GlassScriptPhysician profile
Ramalingam Ratnasabapathy
NPI 1144220781
$25,078.89
in general payments reported to CMS, 2019-2025
61 companies · $5,625 in 2025
The $5,625 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370 · 2020: $832 · 2021: $2,350 · 2022: $2,026 · 2023: $4,899 · 2024: $7,978 · 2025: $5,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $3,545 · Education: $1,053 · Long Term Medical Supply Or Device Loan: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,022.21 |
| Consulting Fee | $3,545.00 |
| Education | $1,053.35 |
| Long Term Medical Supply Or Device Loan | $880.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,783.58 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $2,539.81 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $2,343.67 | 2019-2025 | Phesgo, Perjeta, Polivy |
| Novartis Pharmaceuticals Corporation | $2,328.90 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,325.74 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $1,187.40 | 2021-2025 | |
| Janssen Biotech, INC. | $737.22 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $718.58 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $689.84 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $638.41 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $607.09 | 2019-2025 | Reblozyl, Eliquis |
| Pfizer INC. | $585.77 | 2022-2025 | |
| Astellas Pharma US INC | $577.98 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Exelixis INC. | $574.80 | 2021-2025 | Cabometyx |
| Sobi, INC | $530.14 | 2023-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $490.51 | 2019-2025 | |
| Celgene Corporation | $489.04 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Tempus Ai, INC | $473.91 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $412.76 | 2023-2025 | Xpovio |
| Azurity Pharmaceuticals, INC. | $400.62 | 2025 | Danziten |
| Lilly USA, LLC | $317.85 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Ipsen Biopharmaceuticals, INC | $283.62 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Amgen INC. | $257.81 | 2022-2023 | Lumakras, Kyprolis, Vectibix |
| Eisai INC. | $227.60 | 2022-2025 | |
| Abbvie INC. | $209.71 | 2022-2025 | |
| Genzyme Corporation | $177.54 | 2022-2025 | |
| Emd Serono, INC. | $171.68 | 2023-2025 | Bavencio |
| Glaxosmithkline, LLC. | $144.65 | 2022-2025 | Ojjaara, Jemperli |
| Seagen INC. | $144.57 | 2022-2025 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $132.18 | 2024-2025 | Alunbrig, Fruzaqla |
| Regeneron Pharmaceuticals, INC. | $125.77 | 2025 | Libtayo |
| G1 Therapeutics, INC. | $121.81 | 2022 | |
| Genmab U.S., INC. | $109.72 | 2024-2025 | Tivdak, Epkinly |
| Aveo Pharmaceuticals, INC. | $99.95 | 2024 | |
| Stemline Therapeutics INC. | $93.22 | 2023-2025 | Orserdu |
| Beone Medicines USA, INC. | $84.63 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $76.99 | 2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $74.05 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $73.92 | 2023-2025 | Nerlynx |
| Rigel Pharmaceuticals, INC. | $69.50 | 2022-2023 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $61.61 | 2024 | Brukinsa |
| Secura Bio, INC. | $56.40 | 2019 | |
| Dendreon Pharmaceuticals LLC | $54.72 | 2024 | Provenge |
| Geron Corporation | $47.74 | 2025 | Rytelo |
| Taiho Oncology, INC. | $43.40 | 2024 | |
| Blueprint Medicines Corporation | $42.78 | 2024 | Ayvakit |
| Array Biopharma INC | $30.03 | 2025 | Mektovi, Braftovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $28.63 | 2024 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $27.98 | 2025 | Amvuttra |
| Acrotech Biopharma INC. | $27.14 | 2024 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $26.66 | 2024 | |
| Springworks Therapeutics, INC. | $25.53 | 2024 | Ogsiveo |
| Servier Pharmaceuticals LLC | $23.75 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.37 | 2025 | |
| Recordati_rare_diseases_inc. | $21.63 | 2025 | Enjaymo |
| Adaptive Biotechnologies Corporation | $21.45 | 2025 | Clonoseq |
| Coherus Oncology, INC. | $20.63 | 2024 | |
| Sirtex Medical INC | $20.17 | 2023 | Sir-Spheres Microspheres |
| Accord Healthcare, INC. | $16.32 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.60 | 2021-2023 | Xarelto |
| Foundation Medicine, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramalingam Ratnasabapathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.